BOSTON, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Owen Wallace, Ph.D., the Company's Chief Scientific Officer will be departing from his position to transition to a Chief Executive Officer role at a UK-based biotechnology company. Dr. Wallace will serve as a scientific advisor to Monte Rosa, including as a member of its Scientific Advisory Board (SAB).
The Company's drug discovery organization will continue to be led by a highly accomplished team that includes Sharon Towson, Ph.D., Chief Technology Officer; John Castle, Ph.D., Chief Data and Information Officer; and Magnus Walter Ph.D., Senior Vice President, Drug Discovery.
"We would like to thank Owen for his many contributions to Monte Rosa over the past three years. Owen was instrumental in the development of our QuEEN™ drug discovery engine and the advancement of our MGD drug candidates. We look forward to continuing to benefit from Owen's scientific insights via his new role on our SAB. While Owen will be missed on our team, we wish him every success in his exciting next endeavor," said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics. "The experienced leadership of Sharon, John and Magnus will continue to guide our drug discovery and translational research efforts and we expect no disruption to any of our ongoing work. We look forward to progressing our MGD programs and making a difference in diseases with high unmet medical need."
"I have very much enjoyed my time with Monte Rosa and I am proud of the team and the exceptional company we've built," commented Dr. Wallace. "By harnessing ...